$27.75
-1.05[-3.65%]
Last update: 10:36AM Get Real Time Here
Immunovant
(NASDAQ:IMVT)Latest News for Immunovant Stock (NASDAQ:IMVT)
Immunovant Stock (NASDAQ: IMVT)
Categories: All
Thursday, March 28, 2024
Monday, March 25, 2024
Thursday, March 21, 2024
Wednesday, March 13, 2024
Tuesday, March 12, 2024
Thursday, February 15, 2024
Monday, February 12, 2024
Thursday, December 21, 2023
- Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Dec 21, 2023, 1:01PM
- B of A Securities Maintains Buy on Immunovant, Raises Price Target to $51Benzinga Newsdesk - Dec 21, 2023, 11:29AM
- Immunovant shares are trading higher after the company announced results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves' disease meaningfully exceeded 50% response rates.Benzinga Newsdesk - Dec 21, 2023, 9:06AM
- Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%Vandana Singh - Dec 21, 2023, 8:57AM
- Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For ThursdayAvi Kapoor - Dec 21, 2023, 7:36AM
- HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $51Benzinga Newsdesk - Dec 21, 2023, 6:09AM
- Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market SessionAvi Kapoor - Dec 21, 2023, 5:27AM
Wednesday, December 20, 2023
- Immunovant Says Results From Initial Cohort Of Patients In An Ongoing 24-week Phase 2 Clinical Trial Of Batoclimab In Patients With Graves' Disease Meaningfully Exceeded 50% Response RatesBenzinga Newsdesk - Dec 20, 2023, 4:32PM
- Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Dec 20, 2023, 1:16PM
- FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionAvi Kapoor - Dec 20, 2023, 5:33AM
Tuesday, December 12, 2023
- Immunovant shares are trading higher after Deutsche Bank initiated coverage on the stock with a Buy rating and a $50 price target.Benzinga Newsdesk - Dec 12, 2023, 11:59AM
- Deutsche Bank Initiates Coverage On Immunovant with Buy Rating, Announces Price Target of $50Benzinga Newsdesk - Dec 12, 2023, 5:11AM
Friday, December 01, 2023
Tuesday, November 28, 2023
Wednesday, November 15, 2023
- Truist Securities Maintains Buy on Immunovant, Raises Price Target to $48-Report Released on 14th Nov 2023Benzinga Newsdesk - Nov 15, 2023, 1:13PM
- Where Immunovant Stands With AnalystsBenzinga Insights - Nov 15, 2023, 12:00PM
- Truist Securities Maintains Buy on Immunovant, Raises Price Target to $48Benzinga Newsdesk - Nov 15, 2023, 11:37AM
Thursday, November 09, 2023
Tuesday, October 24, 2023
Monday, October 16, 2023
Friday, October 13, 2023
- Immunovant shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $18 to $55.Bill Haddad - Oct 13, 2023, 11:42AM
- Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023Benzinga Insights - Oct 13, 2023, 11:00AM
- UBS Upgrades Immunovant to Buy, Raises Price Target to $55Benzinga Newsdesk - Oct 13, 2023, 5:48AM
Monday, October 09, 2023
Thursday, October 05, 2023
Thursday, September 28, 2023
Wednesday, September 27, 2023
- What's Going On Pfizer's Subsidiary Biohaven Stock?Vandana Singh - Sep 27, 2023, 1:05PM
- Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Sep 27, 2023, 12:48PM
- Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023Benzinga Insights - Sep 27, 2023, 11:00AM
- MillerKnoll, Hayward Holdings, Ginkgo Bioworks And Other Big Stocks Moving Higher On WednesdayLisa Levin - Sep 27, 2023, 10:28AM
- Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $48Benzinga Newsdesk - Sep 27, 2023, 7:38AM
- Citigroup Maintains Buy on Immunovant, Raises Price Target to $50Benzinga Newsdesk - Sep 27, 2023, 6:53AM
- Raymond James Upgrades Immunovant to Outperform, Announces $40 Price TargetBenzinga Newsdesk - Sep 27, 2023, 4:23AM
Tuesday, September 26, 2023
- Immunovant Reports Proposed Offering Of $300M Of Common StockBenzinga Newsdesk - Sep 26, 2023, 5:02PM
- Nasdaq Down 1.5%; Immunovant Shares Spike HigherLisa Levin - Sep 26, 2023, 2:26PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Sep 26, 2023, 1:31PM
- Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Sep 26, 2023, 12:56PM
- Truist Securities Reiterates Buy on Immunovant, Maintains $30 Price TargetBenzinga Newsdesk - Sep 26, 2023, 12:06PM